Short Interest in Seelos Therapeutics, Inc. (NASDAQ:SEEL) Increases By 178.2%

Seelos Therapeutics, Inc. (NASDAQ:SEEL) was the recipient of a significant growth in short interest in March. As of March 15th, there was short interest totalling 815,000 shares, a growth of 178.2% from the February 29th total of 293,000 shares. Based on an average trading volume of 429,300 shares, the days-to-cover ratio is presently 1.9 days. Currently, 6.5% of the shares of the stock are short sold.

Seelos Therapeutics Price Performance

SEEL stock opened at $0.64 on Thursday. Seelos Therapeutics has a one year low of $0.37 and a one year high of $49.80. The company’s 50 day moving average price is $0.94 and its two-hundred day moving average price is $3.91.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Northern Trust Corp raised its stake in shares of Seelos Therapeutics by 5.1% during the second quarter. Northern Trust Corp now owns 206,171 shares of the company’s stock worth $246,000 after acquiring an additional 9,989 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in Seelos Therapeutics by 7.7% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 264,684 shares of the company’s stock valued at $222,000 after purchasing an additional 19,005 shares during the period. BlackRock Inc. increased its position in Seelos Therapeutics by 1.2% during the 2nd quarter. BlackRock Inc. now owns 1,681,648 shares of the company’s stock valued at $2,010,000 after purchasing an additional 19,590 shares during the period. Goldman Sachs Group Inc. increased its position in Seelos Therapeutics by 15.0% during the 2nd quarter. Goldman Sachs Group Inc. now owns 151,335 shares of the company’s stock valued at $103,000 after purchasing an additional 19,726 shares during the period. Finally, Geode Capital Management LLC increased its position in Seelos Therapeutics by 2.0% during the 1st quarter. Geode Capital Management LLC now owns 1,138,001 shares of the company’s stock valued at $787,000 after purchasing an additional 22,118 shares during the period. 23.37% of the stock is owned by hedge funds and other institutional investors.

Seelos Therapeutics Company Profile

Seelos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD).